NRAS and essential thrombocythemia: Unlike mutant N-Ras-mediated Socs2 downregulation, several hematopoietic malignancies driven by other oncogenic mutations demonstrate upregulated SOCS2 expression, such as JAK2V617F-positive essential thrombocythemia (ET) (Puigdecanet et al., 2008), BCR/ABL-positive CMLs (Vitali et al., 2015) and FLT3-ITD AMLs (Janke et al., 2014).